Braveheart Bio Reports Third Quarter 2026 Financial Results and Provides Business Update
Braveheart Bio, Inc. (BRVE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Braveheart Bio Reports Third Quarter 2026 Financial Results and Provides Business Update 52-week data presented at AHA Scientific Sessions 2026 further strengthen BHB-1893’s potential differentiation, with encouraging clinical activity and support for a highly simpli
How this was made
The 30-second read
Why it matters
The disclosure provides fresh earnings numbers, cash balance, and Phase 2 efficacy data, all first‑reported.
Market read
Earnings and clinical progress are primary catalysts for BRVE; likely to drive short‑term price movement.
What to watch
Potential regulatory delays and reliance on partner Hengrui for Chinese market execution.
Braveheart Bio reports Q3 2026 net loss of $26.5 million, or $0.51 per share, as R&D and G&A rise ahead of LIONHEART-HCM and the company reports $503.5 million in cash
The quarterly net loss narrowed to $(26,495) thousand from $(59,118) thousand, but the prior-year quarter included a $58,770 thousand IPR&D charge for the Hengrui in-license. Operating expenses excluding that charge rose sharply, with R&D at $17,542 thousand against $9 thousand and G&A at $12,607 thousand against $508 thousand. Cash of $503,520 thousand supports a runway the company states extends into 2029.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Research and development expense, three months ended Sep 30, 2026GAAP | $17.54M | – | – |
| In-process research and development expense, three months ended Sep 30, 2026GAAP | nil (shown as a dash in the table) | – | – |
| General and administrative expense, three months ended Sep 30, 2026GAAP | $12.61M | – | – |
| Non-cash stock-based compensation included in G&A, three months ended Sep 30, 2026GAAP | $7.8M | – | – |
| of which liability-classified modified executive restricted stock awards, three months ended Sep 30, 2026GAAP | $6.1M | – | – |
| Total operating expenses, three months ended Sep 30, 2026GAAP | $30.15M | – | – |
| Loss from operations, three months ended Sep 30, 2026GAAP | −$30.15M | – | – |
| Total other income, three months ended Sep 30, 2026GAAP | $3.65M | – | – |
| Net loss, three months ended Sep 30, 2026GAAP | −$26.50M | – | – |
| Net loss per share, basic and diluted, three months ended Sep 30, 2026GAAP | $(0.51) | – | – |
| Research and development expense, nine months ended Sep 30, 2026GAAP | $39.58M | – | – |
| In-process research and development expense, nine months ended Sep 30, 2026GAAP | nil (shown as a dash in the table) | – | – |
| General and administrative expense, nine months ended Sep 30, 2026GAAP | $21.50M | – | – |
| Total operating expenses, nine months ended Sep 30, 2026GAAP | $61.08M | – | – |
| Loss from operations, nine months ended Sep 30, 2026GAAP | −$61.08M | – | – |
| Total other income, nine months ended Sep 30, 2026GAAP | $5.32M | – | – |
| Net loss, nine months ended Sep 30, 2026GAAP | −$55.76M | – | – |
| Deemed dividends upon issuance of redeemable convertible preferred stock, nine months ended Sep 30, 2026GAAP | −$3.62M | – | – |
| Net loss attributable to common stockholders, nine months ended Sep 30, 2026GAAP | −$59.38M | – | – |
| Net loss per share, basic and diluted, nine months ended Sep 30, 2026GAAP | $(2.66) | – | – |
Capital returns
- The release does not report share repurchases or dividends.
- In August 2026 the company completed its upsized IPO, selling 24,437,500 shares of common stock, including the full exercise of the underwriters' option, at $18.00 per share for gross proceeds of approximately $439.9 million. Shares began trading on the Nasdaq Global Market under BRVE on August 6, 2026.
What drove it
- The company states the R&D increase was primarily due to clinical and manufacturing costs to support the initiation and enrollment of LIONHEART-HCM, higher personnel-related costs and a $1.0 million milestone under the Hengrui license agreement.
- The company states the G&A increase was primarily due to personnel-related costs, including stock-based compensation, and consultant and legal costs to support growth and operations as a public company.
- The company states the prior-year quarter included $58.8 million of IPR&D expense related to the in-license of BHB-1893 from Hengrui, and no IPR&D expense was recorded in the current quarter.
- The release reports total other income of $3,654 thousand for the quarter but does not explain its source.
- Clinical data: 52-week open-label extension in 42 patients with oHCM showed mean pVO2 improvement of 2.7 mL/kg/min and KCCQ-CSS improvement of 17.3 points from OLE baseline, with no on-treatment severe or serious adverse events, per the release.
Concerns
- Net loss for the quarter was $(26,495) thousand and for the nine months was $(55,763) thousand, with operating expenses continuing to rise as the Phase 3 program advances.
- Of the $7.8 million non-cash stock-based compensation in G&A, $6.1 million relates to liability-classified modified executive restricted stock awards that are remeasured to fair value each reporting period.
- The release states the company relies on Hengrui for clinical data generation and for manufacturing of BHB-1893.
- The release states the company will need substantial additional funds to complete development and commercialize a product candidate, if approved.
What to watch
- Initiation of NOBLEHEART-HCM, the global Phase 3 in nHCM, which the company plans for the first half of 2027.
- Initiation of TRUEHEART-HCM, the fixed-dose Phase 2b in oHCM, in the U.S., planned for the first half of 2027.
- Topline results from Hengrui's Phase 3 Study 301 of HRS-1893 in oHCM in China, expected in the first half of 2027.
- 52-week data from the nHCM Phase 2 open-label extension, expected in the first half of 2027.
- Interim analysis of LVOT gradient at Week 12 from LIONHEART-HCM, expected in the second half of 2027.
- Cash runway, which the company states extends into 2029.
Balance sheet and cash flow
- Cash, cash equivalents and investments were $503.5 million as of September 30, 2026, compared to $89.2 million as of December 31, 2025 (balance sheet table: $503,520 thousand versus $89,161 thousand).
- Based on the current operating plan, the company estimates existing cash, cash equivalents and investments will be sufficient to fund projected operating expenses and capital expenditure requirements into 2029.
- Total assets were $514,450 thousand at September 30, 2026, compared to $89,350 thousand at December 31, 2025.
- Total liabilities were $16,848 thousand at September 30, 2026, compared to $5,333 thousand at December 31, 2025.
- Redeemable convertible preferred stock was nil at September 30, 2026 (shown as a dash) compared to $149,889 thousand at December 31, 2025.
- Total stockholders' equity was $497,602 thousand at September 30, 2026, compared to a deficit of $(65,872) thousand at December 31, 2025.
- Operating and free cash flow for the period are not reported in the release.
Analysis
Braveheart Bio reported a third quarter 2026 net loss of $(26,495) thousand, or $0.51 per share, against $(59,118) thousand, or $10.05 per share, in the prior-year quarter. The comparison is distorted by the prior-year IPR&D charge of $58,770 thousand tied to the in-license of BHB-1893 from Hengrui. Excluding that line, the cost base has moved from a single-digit-thousand operating base to a Phase 3 spending profile. R&D was $17,542 thousand against $9 thousand, and G&A was $12,607 thousand against $508 thousand. Total operating expenses were $30,149 thousand. The company attributes the R&D rise to LIONHEART-HCM clinical and manufacturing costs, higher personnel costs and a $1.0 million Hengrui milestone, and the G&A rise to personnel costs including stock-based compensation and public-company consultant and legal costs.
For the nine months, the net loss was $(55,763) thousand before a $(3,615) thousand deemed dividend on the issuance of redeemable convertible preferred stock. Net loss attributable to common stockholders was $(59,378) thousand, and the per-share loss was $(2.66). The release reports total other income of $3,654 thousand for the quarter and $5,317 thousand for the nine months, but does not explain its source. Quarterly weighted-average share figures in the table reflect the August 2026 IPO, so per-share comparisons across periods are affected by the change in share count, as the table shows.
On the balance sheet, cash, cash equivalents and investments were $503,520 thousand at September 30, 2026, up from $89,161 thousand at December 31, 2025, after the IPO that raised gross proceeds of approximately $439.9 million at $18.00 per share. Total stockholders' equity moved from a deficit of $(65,872) thousand to $497,602 thousand. Total liabilities were $16,848 thousand. The company states that existing cash will fund projected operating and capital expenditure needs into 2029. Operating cash flow and free cash flow are not disclosed in the release.
Development news is the main content of the release. The company reported 52-week open-label extension data from 42 patients with oHCM, citing pVO2 and KCCQ-CSS improvements, a 67% early Week 1 LVOT-G response below 30 mmHg before titration, and no on-treatment severe or serious adverse events. It also updated its strategy to TRUEHEART-HCM, a fixed-dose 40 mg twice-daily Phase 2b trial, and reported that LIONHEART-HCM is enrolling with a Week 12 interim LVOT analysis expected in the second half of 2027. NOBLEHEART-HCM is planned to start in the first half of 2027 after an end-of-Phase 2 meeting with the FDA. The release gives no guidance figures, so there is no prior outlook to test against.
The key figures for a reader are the step-up in R&D and G&A, the non-recurrence of the IPR&D charge, the non-cash stock-based compensation component of G&A, and the cash position relative to the company's stated runway. The next checkpoints are the first-half 2027 trial starts and the Hengrui Study 301 topline.
Management, verbatim
BHB-1893 continues to show a consistent, potentially differentiated profile across multiple clinical studies and our mechanistic work,
Travis Murdoch, M.D., President and Chief Executive Officer of Braveheart Bio
Not in the filing
stated, not guessed- Prior-quarter (Q2 2026) figures for the income statement lines are not printed in the release.
- Year-over-year and sequential percentage changes are not printed.
- Quarterly and nine-month operating cash flow, investing cash flow and free cash flow are not reported.
- Company-level guidance figures (revenue, margin, operating expenses, tax rate) are not provided.
- No segment or geographic revenue breakdown is provided; the company reports no revenue in the filing.
- Source of total other income ($3,654 thousand quarter; $5,317 thousand nine months) is not explained.
- Share repurchases and dividends are not reported.
- Prior-year nine-month and quarterly cash flow figures are not reported.
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
Braveheart Bio, a clinical‑stage cardiology biotech, filed its Q3 2026 8‑K with financials and trial updates.
Ticker impact
SEC 8‑K reports Q3 2026 results, cash runway to 2029 and encouraging Phase 2 data for BHB‑1893.
potential upside as investors price in robust cash runway and encouraging trial data
First‑report earnings disclosure with material cash balance and Phase 2 efficacy signals; typical catalyst for biotech equities.
Market effects
reinforces optimism in the HCM therapeutic niche and may lift peer biotech valuations.
US biotech sector could see modest gains; limited broader market effect.
minimal global impact beyond biotech investors.
Counterpoint
If trial data later fail to translate into pivotal outcomes, the cash runway may not offset dilution risk.
Key entities
- companyBraveheart Bio, Inc.
Nasdaq‑listed developer of BHB‑1893 for hypertrophic cardiomyopathy.
- partnerHengrui Pharma
Chinese collaborator on Phase 3 oHCM trial.
